出售资产赚了近56亿元,药明康德第三次上调去年营收预期
Di Yi Cai Jing·2026-01-12 12:43

Core Viewpoint - WuXi AppTec (603259.SH, 02359.HK) has raised its revenue forecast for 2025 for the third time, expecting approximately 45.456 billion yuan in revenue, a year-on-year increase of about 15.84%, with a significant net profit forecast of around 19.151 billion yuan, representing a 102.65% increase year-on-year, marking a historical high for the company [1][3]. Group 1 - The company expects 2025 revenue to reach approximately 45.456 billion yuan, with a year-on-year growth of about 15.84%, and a 21.40% increase in revenue from continuing operations [1]. - The previous revenue forecast was adjusted from 42.5-43.5 billion yuan to 43.5-44 billion yuan during the Q3 report [1]. - The anticipated net profit for 2025 is approximately 19.151 billion yuan, which is a historical high and represents a year-on-year increase of about 102.65% [1][3]. Group 2 - The company focuses on a unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, enhancing production efficiency and expanding capabilities to drive steady business growth [3]. - Significant net profit contributions are expected from the sale of assets, including approximately 4.161 billion yuan from the sale of shares in WuXi AppTec's subsidiary and about 1.434 billion yuan from the sale of 100% equity in two clinical research companies, totaling nearly 5.6 billion yuan in net gains [3]. - The asset sales align with the company's strategy to focus on the CRDMO business model, providing funding support for global capacity expansion [3].